Bausch Health Companies (NYSE:BHC) has been assigned a $32.00 price target by equities research analysts at Cantor Fitzgerald in a report issued on Friday, TipRanks reports. The brokerage presently has a “buy” rating on the stock. Cantor Fitzgerald’s price target suggests a potential upside of 54.37% from the company’s current price.

A number of other equities research analysts also recently weighed in on the company. Zacks Investment Research raised Bausch Health Companies from a “hold” rating to a “buy” rating and set a $27.00 price objective on the stock in a research report on Tuesday, May 21st. ValuEngine downgraded Bausch Health Companies from a “hold” rating to a “sell” rating in a research report on Monday, May 20th. Wells Fargo & Co set a $9.00 price objective on Bausch Health Companies and gave the company a “sell” rating in a research report on Friday, May 17th. JPMorgan Chase & Co. raised Bausch Health Companies from an “underweight” rating to a “neutral” rating and set a $24.80 price objective on the stock in a research report on Monday, May 13th. Finally, Mizuho raised their price objective on Bausch Health Companies from $41.00 to $45.00 and gave the company a “buy” rating in a research report on Tuesday, May 7th. Three research analysts have rated the stock with a sell rating, four have issued a hold rating and ten have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $27.99.

BHC stock traded down $0.72 during trading on Friday, reaching $20.73. 5,578,832 shares of the company traded hands, compared to its average volume of 4,523,990. Bausch Health Companies has a 12 month low of $17.20 and a 12 month high of $28.45. The company has a market cap of $7.55 billion, a P/E ratio of 5.16, a PEG ratio of 0.49 and a beta of 0.55. The company has a debt-to-equity ratio of 8.61, a current ratio of 1.08 and a quick ratio of 0.83.

Bausch Health Companies (NYSE:BHC) last issued its quarterly earnings data on Monday, May 6th. The company reported $1.03 earnings per share for the quarter, beating analysts’ consensus estimates of $0.89 by $0.14. Bausch Health Companies had a positive return on equity of 47.01% and a negative net margin of 19.27%. The company had revenue of $2.02 billion for the quarter, compared to the consensus estimate of $2.03 billion. During the same quarter last year, the company earned $0.89 earnings per share. The firm’s revenue for the quarter was up 1.1% compared to the same quarter last year. On average, analysts anticipate that Bausch Health Companies will post 4.15 EPS for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the business. Orbimed Advisors LLC boosted its holdings in Bausch Health Companies by 89.1% in the fourth quarter. Orbimed Advisors LLC now owns 3,600,300 shares of the company’s stock worth $66,498,000 after acquiring an additional 1,696,400 shares in the last quarter. Financial Sense Advisors Inc. boosted its holdings in Bausch Health Companies by 7.7% in the fourth quarter. Financial Sense Advisors Inc. now owns 84,250 shares of the company’s stock worth $1,556,000 after acquiring an additional 6,050 shares in the last quarter. Bank of Nova Scotia boosted its holdings in Bausch Health Companies by 14.6% in the fourth quarter. Bank of Nova Scotia now owns 1,207,147 shares of the company’s stock worth $22,296,000 after acquiring an additional 154,143 shares in the last quarter. Greatmark Investment Partners Inc. boosted its holdings in Bausch Health Companies by 24.2% in the fourth quarter. Greatmark Investment Partners Inc. now owns 18,225 shares of the company’s stock worth $337,000 after acquiring an additional 3,550 shares in the last quarter. Finally, Bessemer Group Inc. acquired a new stake in Bausch Health Companies in the fourth quarter worth about $33,000. 53.68% of the stock is owned by institutional investors and hedge funds.

Bausch Health Companies Company Profile

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.

Recommended Story: The mechanics of the bid-ask spread in trading

Analyst Recommendations for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.